NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 25 April 2024 with key information relating to the
preferential rights issue in the Company (the "Rights Issue"). Please see
updated key information relating to the Rights Issue included below.
Date on which the terms and conditions of the Rights Issue were announced: 25
April 2024
Last day including right: 16 May 2024
Ex-date: 21 May 2024
Record Date: 22 May 2024
Date of approval: 16 May 2024
Maximum number of New Shares: 59,038,955
Subscription price: NOK 1.52442
Ratio preferential rights: Each existing shareholder as of 16 May 2024 (and
being registered as such in Euronext Securities Oslo, the Norwegian Central
Securities Depository, (the VPS) as at the expiry of 22 May 2024 (the record
date)) will be granted 0.437760 subscription rights for each share registered
as held by the shareholder. The number of subscription rights granted to each
existing shareholder will be rounded down to the nearest whole subscription
right.
Subscription ratio: 1:1 (number of new shares per subscription right)
Manager: Carnegie AS
Will the rights be listed: The Company will apply for trading of the
Subscription Rights on Euronext Growth Oslo
ISIN for the preferential rights: To be announced when clarified
Other information: The subscribers in the Rights Issue will without cost be
allocated one warrant issued by the Company for every two new shares allocated
to, and paid by, them in the Rights Issue. The number of warrants to be issued
will be minimum 24,599,564 and maximum 29,519,478. Each warrant will give the
holder a right to subscribe for one new share in the Company at a subscription
price equal to the volume-weighted average price (VWAP) of the Company's
shares on Euronext Growth Oslo on the three last trading days prior to the
first date on which the holder can exercise the warrant in each exercise
period less 30%, but in any event not exceeding NOK 1.98174 (the subscription
price in the Rights Issue plus 30%). The Warrants may be exercised in the
exercise period from 2 June 2025 to 13 June 2025.
The Rights Issue is subject to approval by the Extraordinary General Meeting
to be held on 16 May 2024.
Disclosure regulation
This information is published in accordance with the requirements of the
Continuing Obligations for issuers listed on Euronext Growth Oslo.
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare ASA, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52